Dáil Éireann Debate, Wednesday - 20 April 2016
296. Deputy Michael Moynihan asked the Minister for Health to investigate the possibility of including the medication Frampya for the treatment of multiple sclerosis on the medical card and long-term illness schemes; the reason this is not already included in such schemes; when a decision will be made on this; and if he will make a statement on the matter. [7411/16]
View answerFampridine (brand name Fampyra) has been reimbursed under the Long Term Illness Scheme on a conditional, responder-only basis since 1 October 2015.
The HSE has provided all Neurology Centres with details of the protocol which must be satisfied to enable a patient to qualify for reimbursement.
Reimbursement will be extended where a demonstration of clinical response (based on objective criteria agreed with clinical experts) is recorded and where that clinical response is shown to persist, based on objective measurement at six-monthly intervals. The HSE extends reimbursement in all cases where the criteria meet the requirements of reimbursement protocol.
